Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
DESCRIPTION (Adapted from the Applicant's abstract): The WEHI231 and CH33
immature B-cell lines have served extensively as models for the study of
B-cell tolerance through clonal deletion via apoptosis. The investigator
has recently shown that treatment of these lines with antisera against
surface IgM or TGF-beta-1 leads to a reduction in activity of NF-kappaB/Rel
transcription factors, causing a drop in c-myc expression which induces
apoptosis. Rescue from apoptosis by CD40 ligation leads to maintenance of
NF-kappaB/Rel and c-Myc expression. In Specific Aim 1, the regulation of
expression and role in apoptosis of the NF-kappaB/Rel inhibitor
I-kappaB-beta following anti-IgM and CD40 ligation will be assessed. Also
the control of transcriptional induction of I-kappaB-alpha by TGF-beta-1 and
of its sustained reduction by CD40 ligation will be characterized. In
Specific Aim 2, the functional role of the drop in c-Myc levels in the
induction of apoptosis will be pursued. Myc has been shown to either induce
transcription of E-box driven promoters via interaction with its partner
MAX, or to repress transcription of genes driven by Inr elements. The
investigator has identified an alternate transcript of Max that generates
protein functioning as a dominant negative Max (dMax) in B-cells, which
inhibits c-Myc transactivation. The investigator proposes that expression
of dMax serves to reduce the level of positive transactivation by c-Myc in
immature B-cells, such that a drop in c-Myc levels results in de-repression
of gene transactivation. Therefore, dMax will be characterized: 1) in
different functional B-cell stages; 2) as a negative regulator of
c-Myc-promoted transactivation and apoptosis in myeloid cells; and 3) with
respect to c-Myc de-repression of Inr-mediated transcription. Finally,
since expression of Mad1, the Max binding partner, was induced following the
drop in c-Myc expression and activated apoptosis in WEHI 231 cells following
microinjection, the regulation of Mad1 expression and its role in apoptosis
will be characterized. Together, these studies should provide important
insights into the role of the c-Myc oncogene and NF-kappaB/Rel in the
control of apoptosis of immature B-cells and the induction of tolerance via
clonal deletion.
No Sub Projects information available for 5R01CA036355-15
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA036355-15
Patents
No Patents information available for 5R01CA036355-15
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA036355-15
Clinical Studies
No Clinical Studies information available for 5R01CA036355-15
News and More
Related News Releases
No news release information available for 5R01CA036355-15
History
No Historical information available for 5R01CA036355-15
Similar Projects
No Similar Projects information available for 5R01CA036355-15